PARP1 and ovarian cancer: A recent study showed that HDACi sensitize HR-proficient human ovarian cancer cells to PARP inhibitors [38], and although the authors showed that Pano+Ola combination decreased cell viability and HR repair and enhanced DNA damage, the effects on PARylation were not determined.